Describe the role of the Drug Enforcement Administration (DEA) as it pertains to the PMHNP.

Outline of health issue and existing or necessary health policy and/or politics.
October 15, 2021
Compare the PMHNP practice environment in the state of Texas with a neighboring state
October 15, 2021

Describe the role of the Drug Enforcement Administration (DEA) as it pertains to the PMHNP.

Describe the role of the Drug Enforcement Administration (DEA) as it pertains to the PMHNP.

Safe Prescribing for PMHNP in the state of Texas Essay

Safe Prescribing For PMHNP In The State Of Texas

Describe the role of the Drug Enforcement Administration (DEA) as it pertains to the PMHNP.

Explain your responsibilities when having a DEA number.
Explain how you apply for a DEA number.
Explain the state of Texas requirements for a safe prescribing and prescription monitoring program. Explain your responsibility as a PMHNP to follow these requirements.
Provide an example of a drug you may prescribe from each of the Schedule II-V drug levels. Safe Prescribing for PMHNP in the state of Texas Essay
Safe Prescribing for PMHNP in the State of Texas

The role of the DEA as it pertains to the PMHNP

The Drug Enforcement Agency (DEA) oversees the prescription of controlled substances by PMHNP. The DEA was created by the national government to offer oversight for drugs that have the likelihood of abuse. Grossman and O’Brien (2016) claim that the oversight is intended to safeguard individuals from becoming addicted to these drugs and to avert the diversion or mishandling of these substances into unlawful hands. It is mandatory for every PMHNP who deals with controlled substances to be registered with the DEA and or be accepted by regulation from the DEA registration.

According to Sullivan (2018), the DEA registration gives nurse practitioners federal authority to order or dispense controlled drugs. The aim of the registration is to track the prescribing practices of the nurse practitioners related to controlled drugs, and also to regulate the unauthorized prescription of controlled drugs. Every qualified PMHNP is allotted a distinctive DEA identifier number. Therefore, it is not possible to fill a controlled substance’s prescription that does not contain an approved DEA number. In addition, the DEA offers a practitioner’s manual to assist PMHNPs to understand their obligations under the Controlled Substances Act (which establishes the federal law concerning lawful as well as illicit controlled substances) and to offer direction in compliance with federal regulations (Sullivan, 2018). Safe Prescribing for PMHNP in the state of Texas Essay

The responsibilities of the PMHNP when holding a DEA number

A PMHNP has the responsibility of using the DEA number when prescribing scheduled drugs that are authorized by Texas state laws. In addition, it is the responsibility of the PMHNP to take precautions with controlled substance prescription pads. As Sullivan (2018) alleges, any nurse practitioner with DEA registration might only undertake only those practices that are approved by state law for the State in which they practice. When federal regulations or laws are different from state regulations or laws, the PMHNP is needed to adhere to the more strict facets of both the state and the federal requirements. In most instances, the state regulation is more strict compared to federal regulation and must be abided by in addition to federal regulation. PMHNPs must also have a clear understanding of state regulations and also the DEA regulations related to scheduled drugs. DEA regulations make it illegal for a nurse practitioner to delegate the utilization of her/his DEA registration as well as a signature to another person. Safe Prescribing for PMHNP in the state of Texas Essay


According to Woo and Robinson (2015), prescribers must take safety measures with prescriptions of controlled substances and information incorporated on the scheduled drugs prescription in order to lessen the chance for deceit along with diversion of the drugs to unintended users. PMHNPs must store prescription pads in a safe area. Additionally, they should never sign prescriptions in advance or use prescriptions as notepads. The prescribing PMHNP must print his or her name, DEA number, telephone number and address on the prescription pads to permit for authentication by the pharmacist dispensing the drugs.

How to apply for the DEA number

A PMHNP is eligible to apply for the DEA number from the federal agency if he/she in compliance with local and state regulations. Prior to application for the DEA number, one should contact the board of nursing or licensing authority in the state of practice for a review of the prescriptive authority, and also the prescription of scheduled drugs. As Woo and Robinson (2015) claim, numerous controlled substance state Acts are outlined after federal legislation. Since the scheduling of substances varies across states, PMHNPs must be familiarized with the provisions of the regulations of their state of licensure. Safe Prescribing for PMHNP in the state of Texas Essay

Buppert (2017) asserts that the applicant can fill the form online via the DEA website or via the regional office of the state. If a state necessitates a nurse practitioner to have a separate scheduled drugs licensure, the PMHNP must get this license and attach as a duplicate to the DEA number application. If state law doesn’t approve the PMHNP to prescribe scheduled drugs, there will be no issuance of the DEA number. The applicant must complete the six sections, furnish the application form with a taxpayer identification number and pay for registration fees of 390 dollars, although states might as well charge for the registration

Texas state requirements for a safe prescribing and prescription monitoring program

Texas’ state prescription drug monitoring program (PDMP) was implemented to assist in the mitigation of prescription diversion and misuse, and also for monitoring and analysis of prescription and dispensation of data for scheduled drugs. D’Souza and Eldrige (2019) assert that the PMPD system comprises of autonomous statewide electronic databases which make a track of prescription of scheduled drugs within Texas and in other states. This data may be used by health professionals, entailing PMHNPs to get timely data on prescription practices along with patient behavior. As indicated by Pope and Deer (2017) providers entailing PMHNPs are authorized to use the databases so as to alleviate deviant behaviors like obtaining medications from numerous prescribers. The practitioner is capable of checking the prescription history of a patient when he signs onto the PDMP portal in his state so as to assess prescription medication behavior of each patient.

Schedule II to Schedule V drugs that a PMHNP might prescribe

Schedule II drugs are substances with presently acknowledged medicinal use for and a high potential for misuse and drug dependency. Schedule III drugs are substances with an acknowledged medicinal use and a lower potential for abuse than schedule II and I drugs, Their misuse might lead to low to moderate dependency Schedule IV are drugs with medicinal use and lower potential for abuse than Schedule, II, II and I drugs, whose abuse might lead to limited dependency. Schedule V drugs have medicinal use along with low abuse relative to Schedule Iv drugs. Their abuse might result in limited dependency compared to Schedule IV drugs (Dasgupta, 2015). An example of schedule II, III, IV, and V that a PMHNP might prescribe are Oxycodone, Cassipa, Diazepam, and Ezogabine respectively. Safe Prescribing for PMHNP in the state of Texas Essay


Buppert, C. (2017). Nurse Practitioner’s Business Practice and Legal Guide. Burlington, MA: Jones & Bartlett Publishers.

Dasgupta, A. (2015). A Health Educator’s Guide to Understanding Drugs of Abuse Testing. Burlington, MA: Jones & Bartlett Learning.

D’Souza, R., & Eldrige, J. (2019). Prescription Drug Monitoring Program. Treasure Island, FL: StatPearls Publishing.

Grossman, S., & O’Brien, M. (2016). How to Run Your Nurse Practitioner Business: A Guide for Success. New York: Springer Publishing Company.

Pope, J., & Deer, T. (2017).Treatment of Chronic Pain Conditions: A Comprehensive Handbook. New York: Springer.

Sullivan, D. (2018). Guide to Clinical Documentation. Philadelphia, PA: F.A. Davis

Woo, T., Robinson, M. (2015).Pharmacotherapeutics For Advanced Practice Nurse Prescribers. Philadelphia, PA: F.A. Davis. Safe Prescribing for PMHNP in the state of Texas Essay